Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE versus CHLOROTHIAZIDE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE versus CHLOROTHIAZIDE SODIUM.
CHLOROTHIAZIDE vs CHLOROTHIAZIDE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
500 mg to 1000 mg orally or intravenously once or twice daily.
500 mg to 1 g orally or intravenously once or twice daily.
None Documented
None Documented
Terminal half-life: 45–120 minutes (prolonged in renal impairment); clinical context: short duration requires frequent dosing
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateChlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateTerminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Renal: ~95% (tubular secretion); Fecal: <5%
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Chlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin."